R&D Pipeline - Sparc Life

Asset / Program

MoA

Discovery

Preclinical

Phase 1

Phase 2

Phase 3

Neurology

Vodobatinib
(SCC-138)

c-ABL
Inhibitor

Parkinson’s Disease

Lewy Body Dementia

Alzheimer’s Disease

Oncology

Vodobatinib
(SCO-088)

BCR-ABL
Inhibitor

Refractory CML

SBO-154

Anti-MUC-1 ADC

Multiple Tumors

Immunology

Vibozilimod
(SCD-044)

Selective
S1PR1 Agonist

Psoriasis

Atopic Dermatitis

SCD-153

Undisclosed

Alopecia Areata

Vodobatinib (SCC-138)

Phase 2

c-ABL Inhibitor for Parkinson’s Disease

Vodobatinib (SCC-138)

Phase 2

c-ABL Inhibitor for Lewy Body Dementia

Vodobatinib (SCC-138)

Preclinical

c-ABL Inhibitor for Alzheimer’s Disease

Vodobatinib (SCO-088)

Phase 2

BCR-ABL Inhibitor for Refractory CML

SBO-154

Preclinical

Anti-MUC-1 ADC for Multiple Tumors

Vibozilimod (SCD-044)

Phase 2

Selective S1PR1 Agonist for Psoriasis

Vibozilimod (SCD-044)

Phase 2

Selective S1PR1 Agonist for Atopic Dermatitis

SCD-153

Phase 1

Undisclosed for Alopecia Areata